934180-37-7

Basic information

• Product Name: tert-butyl (1R,3r,5S)-3-hydroxy-9-azabicyclo[3.3.1]nonane-9-carboxylate
• Synonyms: tert-butyl (1R,3r,5S)-3-hydroxy-9-azabicyclo[3.3.1]nonane-9-carboxylate
• CAS NO: 934180-37-7
• Molecular Weight: 241.331
• Mol File: 934180-37-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: tert-butyl (1R,3r,5S)-3-hydroxy-9-azabicyclo[3.3.1]nonane-9-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl (1R,3r,5S)-3-hydroxy-9-azabicyclo[3.3.1]nonane-9-carboxylate(934180-37-7)
• EPA Substance Registry System: tert-butyl (1R,3r,5S)-3-hydroxy-9-azabicyclo[3.3.1]nonane-9-carboxylate(934180-37-7)

Safety Data

• Hazardous Substances Data: 934180-37-7(Hazardous Substances Data)

Usage

General Description

Tert-butyl (1R,3r,5S)-3-hydroxy-9-azabicyclo[3.3.1]nonane-9-carboxylate is a chemical compound with a complex structure that includes a tert-butyl group, a hydroxyl group, and a carboxylate group. The compound also contains a 9-azabicyclo[3.3.1]nonane ring system, which is a fused bicyclic structure. The stereochemistry of the compound is specified by the (1R,3r,5S) designation, indicating the absolute configuration at different carbon atoms in the molecule. tert-butyl (1R,3r,5S)-3-hydroxy-9-azabicyclo[3.3.1]nonane-9-carboxylate may have pharmaceutical or biological applications, but further research and testing would be needed to determine its specific properties and potential uses.

Upstream product

• 72761-60-5 9-azabicyclo<3.3.1>nonan-3-one hydrochloride 
• 552-70-5 pseudopelletierine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 512822-27-4 tert-butyl 3-oxo-9-azabicyclo[3.3.1]nonane-9-carboxylate 
• 504-12-1 exo-9-azabicyclo[3.3.1]nonan-3-ol 

Relevant articles and documents

THERAPEUTICALLY ACTIVE BICYCLIC-SULPHONAMIDES AND PHARMACEUTICAL COMPOSITIONS

Pharmaceutical compounds have a bicyclic-sulphonamide structure and pharmaceutical compositions including the compounds may be used in therapy as brain-cell-death protectants and may be used, for example, in the treatment of chronic neurodegenerative diseases. The compounds are active as inhibitors of N-acylethanolamine-hydrolysing acid amidase (NAAA) and may be used for the therapeutic treatment and prevention of pain and inflammatory disorders and other disorders which benefit from the modulation of fatty acid ethanolamides, particularly palmitoylethanolamide (PEA).

9-AZABICYCLO [3 . 3 . 1] NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS

The present invention relates to a 9-azabicyclo[3.3.1]nonane derivative of formula (I), wherein R1 is H or C1-5alkyl; X is O or NR2, wherein R2 is H, C1-5alkyl or C2-5acyl and Ar is C6-10aryl or a 5-10 membered heteroaryl ring system, both being optionally substituted with one to three of R3-R5 independently selected from halogen, C1-5alkyl, C1-5alkoxy, C3-6cycloalkyl, C2-5alkenyl, C2-5alkynyl, CN, NO2, hydroxy, phenyl, phenoxy and phenylC1-2alkoxy, wherein said C1-5alkyl and C1-5alkoxy are optionally substituted with one to three halogens and wherein said phenyl, phenoxy and phenylC1-2alkoxy are optionally substituted with one to three substituents independently selected from halogen and methyl or two of R3-R5 at adjacent positions together form a methylenedioxy or propylene unit, with the proviso that the compounds exo-9-methyl-3-phenoxy-9-azabicyclo[3.3.1]nonane and N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1H indazole-5-amine are excluded, or a pharmaceutically acceptable salt or solvate thereof. The invention also relates to pharmaceutical compositions comprising said 9-azabicyclo[3.3.1]nonane derivatives and to their use in therapy.